(Note: IPOScoop has NO Call on this micro-cap unit offering. Each unit consists of one share of common stock and one warrant to buy one share of common stock.)

We are a clinical biopharmaceutical company whose first product candidate, RenovoGem, is a drug and device combination of intra-arterial gemcitabine and RenovoCath. The FDA has granted orphan drug designation for RenovoGem for our first two indications – pancreatic cancer and bile duct cancer.

**The revenue and net loss figures are for the 12 months that ended June 30, 2021.

(Note: RenovoRx priced its IPO on Aug. 25, 2021, at $9 – the low end of its $9-to-$11 range – and sold 1.85 million units, up from 1.8 million units in its prospectus, to raise $16.65 million. RenovoRx had downsized its IPO to 1.8 million units – down from 1.85 million – and cut the price range to $9 to $11 – down from $11 to $13 – in an S-1/A filing dated Aug. 25, 2021.)